Northwestern Mutual Wealth Management Co. Sells 39,053 Shares of Pfizer Inc. (NYSE:PFE)

Northwestern Mutual Wealth Management Co. lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 4.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 853,001 shares of the biopharmaceutical company’s stock after selling 39,053 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Pfizer were worth $23,867,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Olistico Wealth LLC acquired a new position in Pfizer during the 2nd quarter worth $25,000. MFA Wealth Advisors LLC acquired a new stake in Pfizer in the 2nd quarter valued at approximately $29,000. Creekmur Asset Management LLC bought a new position in Pfizer in the 4th quarter worth approximately $32,000. Trivant Custom Portfolio Group LLC boosted its position in shares of Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares during the period. Finally, Financial Connections Group Inc. bought a new stake in shares of Pfizer in the second quarter valued at approximately $34,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.5 %

NYSE PFE opened at $28.94 on Tuesday. The stock has a fifty day moving average of $29.29 and a 200-day moving average of $28.30. The stock has a market capitalization of $163.96 billion, a P/E ratio of -482.25, a price-to-earnings-growth ratio of 1.27 and a beta of 0.68. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $34.11. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.14. The company had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.67 EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.66 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on PFE. Wells Fargo & Company upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday, September 16th. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. UBS Group raised their price objective on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Finally, Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Eight investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.